CA-NEXON-AMERICA
7.6.2022 15:03:34 CEST | Business Wire | Press release
MapleStory , Nexon ’s original free-to-play, side scrolling 2D MMORPG with an aggressively cute game style, announces the first of its two-part summer update, “Destiny: Remastered,” lands in-game on June 15, filled to the brim with special events, a revamp of all of Explorer jobs, plus a gift package for pre-registering before June 13!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005606/en/
SPECIAL EVENTS
Summer just wouldn’t be summer in MapleStory
without some special, in-game events! It’s time for the season of music and majesty, as new friend Stella comes to experience Maple World first hand. There are a wealth of rewards to collect during the musical summer nights of Starlight Symphony
, plus the return of Tera Burning Plus
and Burning World
. On top of all that, pre-register a character (must be level 61 or above) before 11am PDT on June 13 to get a special Destiny gift package featuring Lil Symphony pets, Angelic Alphabet Damage Skin, a heap of Melody Coins to get a head start in Starlight Symphony, and a Magician of the Sacred Forest outfit!
EXPLORER REVAMP
The Explorer class of characters in MapleStory
has been the backbone of the game for the last seventeen years. These 14 unique Explorer jobs are receiving a complete overhaul of animations, improved skills, new story segments, and more.
The Explorer revamp benefits the following characters:
- Warrior : Hero, Paladin, Dark Knight
- Magician : Arch Mage (Fire/Poison), Arch Mage (Ice/Lightning), Bishop
- Bowman : Bowmaster, Marksman
- Thief : Night Lord, Shadower, Dual Blade
- Pirate : Corsair, Buccaneer, Cannoneer
IMPROVEMENTS GALORE
Incorporated into the “Destiny: Remastered” update are additional improvements, new boss accessories, and boss difficulties so everyone can enjoy a better Maple experience:
- No more Mastery Books ! - Mastery Books are no longer needed to upgrade 4th Job skills.
- Dawn Boss Accessories set - Claim a new set of accessories from bosses to forge a powerful new set.
- New Boss Difficulties - Take on Chosen Seren and Verus Hilla on normal mode and overcome Will on easy difficulty.
BEAN BRIGADE “DESTINY: REMASTERED” SNEAK PEEK
Members of MapleStory
’s content creator program, Bean Brigade
, will be jumping into the test servers early beginning today to give Maplers a sneak peek of all the exciting changes and updates coming to “Destiny: Remastered.” Follow along on Bean Brigade’s dedicated Twitch page
from June 7 through 10.
SUMMER UPDATE PART TWO
Last but not least, Summer Update Part Two, “Destiny: Homecoming,” arrives on July 20
with an all-new homestead feature allowing Maplers to purchase and decorate their very own home! Show off your exquisite taste and home decorating style, and be the envy of every other homeowner in Maple World. Also in Part Two, the Watcher Kalos awaits on top of Karote, the Unending Tower. Win in the battle against this formidable boss to obtain a new Eternal Equipment Set!
Grab your sunscreen and check out everything there is to do in MapleStory this summer!
Assets: HERE
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory
https://maplestory.nexon.net
MapleStory
is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory
services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 17 years ago. There have been over 274 million characters created to date, which would make MapleStory
’s Maple World the 4th highest populated country in the world.
About Nexon America Inc.
https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory
and Mabinogi
for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005606/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom